1. Home
  2. JTAI vs JAGX Comparison

JTAI vs JAGX Comparison

Compare JTAI & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$0.30

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.76

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JTAI
JAGX
Founded
2018
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
JAGX
Price
$0.30
$0.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$11.00
$60.00
AVG Volume (30 Days)
28.7M
10.4M
Earning Date
11-14-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,584,279.00
$11,785,000.00
Revenue This Year
N/A
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.45
52 Week Low
$0.26
$0.64
52 Week High
$11.77
$25.75

Technical Indicators

Market Signals
Indicator
JTAI
JAGX
Relative Strength Index (RSI) 26.40 42.54
Support Level $0.26 $0.68
Resistance Level $0.43 $0.99
Average True Range (ATR) 0.11 0.19
MACD 0.02 -0.01
Stochastic Oscillator 3.72 9.19

Price Performance

Historical Comparison
JTAI
JAGX

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: